Chronic Lymphocytic Leukemia (CLL) clinical trials
Showing 101–150 of 175 active trials. Describe your situation to see which ones look like a fit.
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Auto Stem Cell Transplant for Lymphoma Patients
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
- Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- 64Cu-LLP2A for Imaging Hematologic Malignancies
- Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
- Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
- A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
- Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
- Understanding Chronic Lymphocytic Leukemia
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
- Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
- HPC Offered for PRESERVE Expansion
- Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
- Family Study of Lymphoproliferative Disorders
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
- Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
- The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
- GM-CSF With Post-Transplant Cyclophosphamide
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.